Human Serum is as Efficient as Fetal Bovine Serum in Supporting Proliferation and Differentiation of Human Multipotent Stromal (Mesenchymal) Stem Cells In Vitro and In Vivo
- 680 Downloads
Human multipotent stromal (skeletal, mesenchymal) stem cells (hMSC) are employed in an increasing number of clinical trials for tissue regeneration of age-related degenerative diseases. However, routine use of fetal bovine sera (FBS) for their in vitro expansion is not optimal and may pose a health risk for patients.
We carried out a side-by-side comparison of the effects of allogenic pooled human serum (HuS) versus FBS on hMSC proliferation and differentiation in vitro and in vivo. As a model for hMSC, we employed telomerase-immortalized hMSC; hMSC-TERT cell line.
hMSC-TERT exhibited similar morphology and size when cultured in HuS vs. FBS as assessed by light microscopy and FACS analysis. We did not observe any significant differences in growth rates of hMSC-TERT during short-term (10 days) and long-term (100 days) culture in media supplemented with HuS vs. FBS. hMSC-TERT or primary bone marrow derived hMSC induced to osteoblastic or adipocytic differentiation in the presence of HuS or FBS showed comparable levels of gene expression and protein production of osteoblastic markers (CBFA1/Runx2, alkaline phosphastase, collagen type I and osteocalcin) or adipocytic markers (PPAR-gamma2, lipoprotein lipase (LPL), aP2), respectively. In order to test for the functional capacity of hMSC-TERT that have been maintained in long-term cultures in the presence of HuS vs. FBS, the cells were mixed with hydroxyapatite/tricalcium phosphate (HA/TCP) and implanted subcutaneously in immune deficient mice. hMSC maintained in HuS vs. FBS formed comparable heterotopic bone.
Human serum can support proliferation and differentiation of hMSC in vitro and can maintain their bone forming capacity in vivo. The use of human serum in cell cultures of hMSC intended for cell-based therapy is preferable.
KeywordsHuman mesenchymal stem cells Stromal stem cells Fetal bovine serum Human serum Osteoblast differentiation Adipocyte differentiation
The study was supported by grants from the Novo Nordisk Foundation, the Lundbeck foundation and grants from the Region of Southern Denmark and King Abdulaziz City for Science and Technology (09-BIO740-20).
Disclosure of Interest
The authors disclose no conflict of interest
- 4.Sundin, M., Ringden, O., Sundberg, B., Nava, S., Gotherstrom, C., & Le Blanc, K. (2007). No alloantibodies against mesenchymal stromal cells, but presence of anti-fetal calf serum antibodies, after transplantation in allogeneic hematopoietic stem cell recipients. Haematologica, 92, 1208–1215.PubMedCrossRefGoogle Scholar
- 8.Lin, H. T., Tarng, Y. W., Chen, Y. C., Kao, C. L., Hsu, C. J., Shyr, Y. M., et al. (2005). Using human plasma supplemented medium to cultivate human bone marrow-derived mesenchymal stem cell and evaluation of its multiple-lineage potential. Transplantation Proceedings, 37, 4504–4505.PubMedCrossRefGoogle Scholar
- 12.Goedecke, A., Wobus, M., Krech, M., Munch, N., Richter, K., Holig, K., Bornhauser, M. (2010). Differential effect of platelet-rich plasma and fetal calf serum on bone marrow-derived human mesenchymal stromal cells expanded in vitro. Journal of Tissue Engineering and Regenerative Medicine: [Epub ahead of print]Google Scholar
- 17.Abdallah, B. M., Haack-Sorensen, M., Burns, J. S., Elsnab, B., Jakob, F., Hokland, P., et al. (2005). Maintenance of differentiation potential of human bone marrow mesenchymal stem cells immortalized by human telomerase reverse transcriptase gene despite of extensive proliferation. Biochemical and Biophysical Research Communications, 326, 527–538.PubMedCrossRefGoogle Scholar
- 18.Simonsen, J. L., Rosada, C., Serakinci, N., Justesen, J., Stenderup, K., Rattan, S. I. S., et al. (2002). Telomerase expression extends the proliferative life-span and maintains the osteogenic potential of human bone marrow stromal cells. Nature Biotechnology, 20, 592–596.PubMedCrossRefGoogle Scholar
- 19.Larsen, K. H., Frederiksen, C. M., Burns, J. S., Abdallah, B. M., & Kassem, M. (2010). Identifying a molecular phenotype for bone marrow stromal cells with in vivo bone-forming capacity. JBMR, 25, 796–808.Google Scholar
- 22.Shahdadfar, A., Frønsdal, K., Haug, T., Reinholt, F. P., & Brinchmann, J. E. (2005). In vitro expansion of human mesenchymal stem cells: Choice of serum is a determinant of cell proliferation, differentiation, gene expression, and Transcriptome stability. Stem Cells, 23, 1357–1366.PubMedCrossRefGoogle Scholar
- 26.Nimura, A., Muneta, T., Koga, H., Mochizuki, T., Suzuki, K., Makino, H., et al. (2008). Increased proliferation of human synovial mesenchymal stem cells with autologous human serum: Comparisons with bone marrow mesenchymal stem cells and with fetal bovine serum. Arthritis and Rheumatism, 58, 501–510.PubMedCrossRefGoogle Scholar
- 27.Abdallah, B. M., Ditzel, N., Kassem, M. (2008). Assessment of bone formation capacity using in vivo transplantation assays: Procedure and tissue analysis. In: J. J. Westendorf (Ed.), Osteoporosis, vol. 455. pp. 98–100. SpringerGoogle Scholar
- 29.Dahl, J. A., Duggal, S., Coulston, N., Millar, D., Melki, J., Shahdadfar, A., et al. (2008). Genetic and epigenetic instability of human bone marrow mesenchymal stem cells expanded in autologous serum or fetal bovine serum. The International Journal of Developmental Biology, 53, 1033–1042.CrossRefGoogle Scholar